Giiant Pharma
Designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | N/A | Grant |
| Total Funding | 000k | ||
Related Content
Giiant Pharma Inc. specializes in developing gut-restricted, small molecule, tissue-specific drug therapeutics aimed at treating inflammatory bowel diseases (IBD). The company focuses on precision delivery to ensure that the drugs act locally within the gut, thereby minimizing systemic exposure and enhancing patient safety. This approach aims to improve the overall care and treatment outcomes for IBD patients. Giiant Pharma operates within the pharmaceutical industry, targeting healthcare providers and patients suffering from IBD. The business model revolves around the research, development, and commercialization of these specialized therapeutics. Revenue is generated through the sale of these drugs, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The company recently secured $11 million in Seed financing to advance its Precision Delivery technology platform, underscoring its commitment to innovation and effective treatment solutions.
Keywords: gut-restricted, small molecule, IBD, precision delivery, tissue-specific, drug therapeutics, minimal systemic exposure, patient safety, pharmaceutical, Seed financing.